Samir Parekh, MBBS

Samir Parekh, MD, is Professor of Medicine (Hematology and Medical Oncology) and Oncological Sciences at the Icahn School of Medicine at Mount Sinai. He is Director of the Center of Excellence for Multiple Myeloma and Section Head of Multiple Myeloma in the Division of Hematology and Medical Oncology. Dr. Parekh is Co-Leader of the Cancer Clinical Investigation program at The Tisch Cancer Institute at Icahn Mount Sinai and a faculty member of the Icahn Genomics Institute and Marc and Jennifer Lipschultz Precision Immunology Institute. 

Dr. Parekh's research focuses on the pathogenesis of hematological malignancies and development of individualized, precision-medicine therapies for these malignancies. His lab uses an integrated systems biology approach to study genome-wide methylation, gene expression and DNA sequence variation to understand pathogenesis, develop biomarkers and guide personalized therapy in B cell malignancies, particularly multiple myeloma and Non-Hodgkin's lymphoma.

Dr. Parekh currently serves on grant review committees for the National Institutes of Health, Department of Defense and Multiple Myeloma Research Foundation; he is a member of the American Society of Hematology Plasma cell committee and the American Society of Clinical Investigation. Dr. Parekh has led innovative investigator-initiated precision medicine trials testing novel small molecules and NGS-guided drug repurposing using RNA-and DNA-sequencing to salvage end-stage myeloma patients. His lab has served as an international reference unit for studying the immune effects of novel cereblon modulators (Celmods) Iberdomide and Mezigdomide. His observations on the side effects of CART and bispecific therapy have led to increased safety, better patient selection and awareness of infectious complications of these powerful novel therapeutics.

The Parekh Lab